
National Research Corporation NRC
$ 17.86
-4.7%
Quarterly report 2026-Q1
added 05-06-2026
National Research Corporation General and Administrative Expenses 2011-2026 | NRC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.8 M | 44.9 M | 46.6 M | 42.7 M | 39 M | 34.4 M | 33 M | 31.4 M | 29.7 M | 28.4 M | 27.2 M | 25 M | 25.2 M | 23.5 M | 23.3 M | 20.2 M | 16 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.8 M | 16 M | 32.1 M |
Quarterly General and Administrative Expenses National Research Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.4 M | 12.3 M | 17.7 M | 10.4 M | - | 11 M | 11.2 M | 11.2 M | - | 11.8 M | 12 M | 11.8 M | - | 10.8 M | 10.7 M | 10.6 M | - | 9.52 M | 10 M | 9.52 M | - | 7.95 M | 8.85 M | 8.75 M | - | 8.71 M | 8.32 M | 7.71 M | - | 7.68 M | 7.94 M | 7.87 M | - | 8.43 M | 6.9 M | 6.69 M | - | 7.14 M | 7.27 M | 7.36 M | - | 6.62 M | 6.64 M | 7.63 M | - | 5.8 M | 5.98 M | 6.37 M | - | 6.02 M | 6.39 M | 6.49 M | - | 5.82 M | 5.57 M | 6.15 M | - | 5.57 M | 5.99 M | 6.09 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.7 M | 5.57 M | 8.58 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Myriad Genetics
MYGN
|
257 M | $ 4.11 | -18.29 % | $ 381 M | ||
|
Koninklijke Philips N.V.
PHG
|
628 M | $ 27.23 | 2.95 % | $ 20 B | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 17.01 | -0.09 % | $ 179 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 117.69 | 0.14 % | $ 35.8 B | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 20.94 | 1.16 % | $ 1.12 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.64 | 3.14 % | $ 2.18 M | ||
|
Castle Biosciences
CSTL
|
229 M | $ 24.75 | 0.61 % | $ 687 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Medpace Holdings
MEDP
|
198 M | - | - | $ 12.3 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 181.73 | -1.97 % | $ 9.01 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
273 M | $ 8.89 | 0.34 % | $ 1.14 B | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Natera
NTRA
|
589 M | $ 215.09 | 4.02 % | $ 21.2 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 14.92 | 0.13 % | $ 451 M | ||
|
Personalis
PSNL
|
46.2 M | $ 6.07 | 9.17 % | $ 360 M | ||
|
Guardant Health
GH
|
211 M | $ 92.25 | 3.05 % | $ 11.6 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 52.94 | 0.04 % | $ 2.69 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 124.13 | 2.32 % | $ 10.2 B | ||
|
Illumina
ILMN
|
1.09 B | $ 142.58 | 2.52 % | $ 22.7 B | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 5.36 | 7.2 % | $ 224 M | ||
|
Interpace Biosciences
IDXG
|
9.48 M | - | - | $ 9.33 M | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 472.95 | 1.33 % | $ 178 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.21 | 1.14 % | $ 5.08 M | ||
|
Trinity Biotech plc
TRIB
|
28.8 M | $ 0.6 | 0.42 % | $ 61.9 M | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 86.15 | 0.38 % | $ 5.81 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 256.94 | -0.08 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | $ 59.53 | 4.99 % | $ 3.56 B | ||
|
Celcuity
CELC
|
27.2 M | - | - | $ 6.52 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.18 | -0.97 % | $ 1.99 B | ||
|
Waters Corporation
WAT
|
240 M | $ 349.53 | 1.98 % | $ 20.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 189.13 | -0.9 % | $ 21 B |